Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
by
Galetta, Domenico
, Longo, Vito
, Montrone, Michele
, Pesola, Francesco
, Pizzutilo, Pamela
, Catino, Annamaria
, Marerch, Ilaria
in
Adrenal glands
/ Bones
/ Cancer therapies
/ Carcinoma, Non-Small-Cell Lung - therapy
/ Chemotherapy
/ Humans
/ Immunotherapy
/ Italy
/ Laboratories
/ Lung cancer
/ Lung Neoplasms - drug therapy
/ Medical prognosis
/ Metastasis
/ Oncology
/ Original
/ Patients
/ predictive factors
/ Prognosis
/ prognostic factors
/ Radiation therapy
/ Retrospective Studies
/ small cell lung cancer
/ Small Cell Lung Carcinoma - drug therapy
/ Survival analysis
2022
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
by
Galetta, Domenico
, Longo, Vito
, Montrone, Michele
, Pesola, Francesco
, Pizzutilo, Pamela
, Catino, Annamaria
, Marerch, Ilaria
in
Adrenal glands
/ Bones
/ Cancer therapies
/ Carcinoma, Non-Small-Cell Lung - therapy
/ Chemotherapy
/ Humans
/ Immunotherapy
/ Italy
/ Laboratories
/ Lung cancer
/ Lung Neoplasms - drug therapy
/ Medical prognosis
/ Metastasis
/ Oncology
/ Original
/ Patients
/ predictive factors
/ Prognosis
/ prognostic factors
/ Radiation therapy
/ Retrospective Studies
/ small cell lung cancer
/ Small Cell Lung Carcinoma - drug therapy
/ Survival analysis
2022
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
by
Galetta, Domenico
, Longo, Vito
, Montrone, Michele
, Pesola, Francesco
, Pizzutilo, Pamela
, Catino, Annamaria
, Marerch, Ilaria
in
Adrenal glands
/ Bones
/ Cancer therapies
/ Carcinoma, Non-Small-Cell Lung - therapy
/ Chemotherapy
/ Humans
/ Immunotherapy
/ Italy
/ Laboratories
/ Lung cancer
/ Lung Neoplasms - drug therapy
/ Medical prognosis
/ Metastasis
/ Oncology
/ Original
/ Patients
/ predictive factors
/ Prognosis
/ prognostic factors
/ Radiation therapy
/ Retrospective Studies
/ small cell lung cancer
/ Small Cell Lung Carcinoma - drug therapy
/ Survival analysis
2022
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
Journal Article
Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
2022
Request Book From Autostore
and Choose the Collection Method
Overview
Background Potential relationships with the prognosis of patients with extensive‐stage non‐small cell lung cancer (ES‐SCLC) have been investigated without valid results. Methods A retrospective analysis of real‐world data of consecutive patients with ES‐SCLC admitted to our Medical Thoracic Oncology Unit was carried out from 2010 to 2020, focusing on identification of prognostic factors. Kaplan–Meier analysis was used to represent progression‐free survival (PFS) and overall survival (OS). Univariable and multivariable Cox models were used to investigate prognostic factors. Results The analysis included 244 patients. The median OS was 8 months (95% confidence interval [CI]: 8–10) and the median PFS was 5 months (95% CI: 5–6). The univariable analysis showed that factors associated with shorter OS were older age (p = 0.047), TNM stage 4 versus 3 (p < 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 and 2 versus 0 (p < 0.001), and >2 metastatic sites (p = 0.004). Mediastinal radiotherapy (RT) (p < 0.001), >1 irradiated site (p = 0.026), 3 and 4 chemotherapy (CT) lines versus 1 (p = 0.044 and 0.001, respectively), prophylactic cranial irradiation (PCI) (p < 0.001), and surgery (p = 0.001) correlated with longer OS. The multivariable analysis revealed statistically significant associations for TNM, ECOG PS 2 versus 0, number of CT lines, PCI, and surgery. A total of 23 patients (9.4%) survived ≥24 months, 39% of whom had received four CT lines and 48% had mediastinal RT. Conclusions Our data suggest that tumor burden, PS, and mediastinal RT strongly correlate with outcome. With the addition of immunotherapy to CT, the identification of new biomarkers as predictive factors is urgently required. A retrospective analysis of real‐world data of consecutive patients with ES‐SCLC admitted to our Medical Thoracic Oncology Unit was carried out from 2010 to 2020, focusing on identification of prognostic factors. Kaplan–Meier analysis was used to represent progression‐free survival (PFS) and overall survival (OS). Univariable and multivariable Cox models were used to investigate prognostic factors. The analysis included 244 patients. The median OS was 8 months (95% confidence interval [CI]: 8–10) and the median PFS was 5 months (95% CI: 5–6). The univariable analysis showed that factors associated with shorter OS were TNM stage 4 versus 3 (p < 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 and 2 versus 0 (p < 0.001), and >2 metastatic sites (p = 0.004). Mediastinal radiotherapy (RT) (p < 0.001), >1 irradiated site (p = 0.026), 3 and 4 chemotherapy (CT) lines versus 1 (p = 0.044 and 0.001, respectively), prophylactic cranial irradiation (PCI) (p < 0.001) correlated with longer OS. The multivariable analysis revealed statistically significant associations for TNM, ECOG PS 2 versus 0, number of CT lines, and PCI.
Publisher
John Wiley & Sons Australia, Ltd,John Wiley & Sons, Inc,Wiley
This website uses cookies to ensure you get the best experience on our website.